- Home
- LXEO vs NCZ Comparison
LXEO vs NCZ Comparison
Compare LXEO & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LXEO | NCZ |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 288.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEO | NCZ |
|---|---|---|
| Price | $4.28 | $15.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 679.5K | 36.8K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.16% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $12.95 |
| 52 Week High | $10.99 | $16.17 |
Technical Indicators
Market Signals| Indicator | LXEO | NCZ |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 41.98 |
| Support Level | $4.01 | $15.09 |
| Resistance Level | $5.38 | $15.87 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 5.59 | 21.88 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.